Global Insulin Secretagogue Market Size is Predicted to Expand and Reach USD 6.35 Billion by 2035 | CAGR of 8.73%

Global Insulin Secretagogue Market Size is Predicted to Expand and Reach USD 6.35 Billion by 2035

According to a research report published by Spherical Insights & Consulting, the Global Insulin Secretagogue Market is expected to grow from USD 2.53 billion in 2024 to USD 6.35 billion by 2035, at a CAGR of 8.73% during the forecast period 2025-2035.

Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the "Global Insulin Secretagogue Market Size, Share, and COVID-19 Impact Analysis, By Type (Sulfonylurea, Meglitinides, and Others), By Route Of Administration (Oral, Parenteral, and Others), By End Users (Hospitals, Specialty Clinics, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035. " Get Detailed Report Description Here : https://www.sphericalinsights.com/reports/insulin-secretagogue-market  

The insulin secretagogue market refers to the worldwide industry that focuses on medications (sulfonylureas, glinides, DPP-4 inhibitors) that stimulate the pancreas to produce more insulin for type 2 diabetes management. An insulin secretagogue defined as substance stimulating the secretion of insulin from the pancreas, contributing to the regulation of blood glucose levels. There is a surging use of CGM (continuous glucose monitoring) that promote personalized dosing and the development of agents targeting specific pancreatic receptors, effectively managing postprandial glucose. The increased prevalence of diabetes, as well as the adoption of oral antidiabetic insulin secretagogues, is responsible for driving the market demand. Advancements in drug formulation, with an increasing awareness about diabetes management contributes to promoting market growth. On the contrary, medication adverse effects and regulatory hurdles, as well as competition from newer and more effective drug classes, are restraining the market growth.

The sulfonylurea segment dominated the market with the largest share of around 46.1% in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the type, the insulin secretagogue market is divided into sulfonylurea, meglitinides, and others. Among these, the sulfonylurea segment dominated the market with the largest share of around 46.1% in 2024 and is projected to grow at a substantial CAGR during the forecast period. sulfonylureas directly stimulating the pancreatic beta cells to secrete more insulin regardless of blood glucose levels. The preference for sulfonylureas due to their effectiveness, accessibility, and affordability is promoting the segmental market growth.

The oral segment accounted for the largest share of over 50.0% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.

Based on the route of administration, the insulin secretagogue market is divided into oral, parenteral, and others. Among these, the oral segment accounted for the largest share of over 50.0% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Insulin secretagogue are typically taken orally before meals. Trend of home-based care with telemedicine-driven monitoring, patient education and preference for less invasive treatment are anticipated to propel the market demand.

The hospitals segment dominated the market with the largest share of over 50.0% in 2024 and is expected to grow at a significant CAGR during the projected period.

Based on the end users, the insulin secretagogue market is divided into hospitals, specialty clinics, and others. Among these, the hospitals segment dominated the market with the largest share of over 50.0% in 2024 and is expected to grow at a significant CAGR during the projected period. The hospital pharmacist plays an important role in ensuring the safe and effective implementation of inpatient hyperglycemic control and insulin usage. Further, hospitals are central to clinical trials and post-marketing studies.

North America is expected to hold the majority share of the global insulin secretagogue market during the forecast period.

North America is expected to hold the major share of about 39.9% in the global insulin secretagogue market during the forecast period. The U.S. is capturing the dominant market share of about 42.0% within the region in 2024, due to the increased prevalence of diabetes and the presence of a well-established healthcare infrastructure, for providing effective patient care. North America has a robust market ecosystem that includes innovation in diabetic care with the emergence of innovative insulin secretagogue products. Further, the presence of well-established key players and strategic moves for promoting insulin secretagogue products is significantly propelling the market.

Asia Pacific is anticipated to grow at the fastest pace of CAGR 22.0% in the global insulin secretagogue market during the forecast period. India is leading the Asia Pacific insulin secretagogue market, with the largest revenue share in the region, driven by an increasing number of diabetes patients and preference for affordable oral insulin secretagogue medications. In the Asia Pacific Insulin Secretagogue market, there is increased accessibility of oral antidiabetic therapies of insulin secretagogues via expanding hospital networks, specialty clinics, and pharmacy networks in the region. An increasing prevalence of diabetes and lifestyle-related disorders like obesity is responsible for propelling the market.  

Major vendors in the global insulin secretagogue market are Lilly USA, LLC., Novo Nordisk A/S, Sanofi, Merck & Co., Inc., AstraZeneca, Takeda Pharmaceutical Company Limited, Biocon Ltd., Abbott, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Sandoz International GmbH, Cadila Pharmaceuticals Ltd., and Others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Key Market Development 

• In January 2026, Viatris Inc., a global healthcare company, announced the launch of Inpefa (sotagliflozin) in the United Arab Emirates (UAE), the first country within the Viatris territories to commercialize the treatment.

• In October 2023, Zydus Lifesciences Limited announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for ZITUVIO (Sitagliptin) tablets, 25 mg, 50 mg, and 100 mg.

• In October 2023, as per the study EASD (European Association for the Study of Diabetes), food insecurity doubles the rate of severe hypoglycemia in diabetic adults, especially among those using insulin and/or secretagogues. 

• In June 2023, Lexicon Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration had approved INPEFA, a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the insulin secretagogue market based on the below-mentioned segments:

Global Insulin Secretagogue Market, By Type 

• Sulfonylurea
• Meglitinides
• Others

Global Insulin Secretagogue Market, By Route Of Administration

• Oral
• Parenteral
• Others

Global Insulin Secretagogue Market, By End Users

• Hospitals
• Specialty Clinics
• Others

 Global Insulin Secretagogue Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter